Literature DB >> 17659182

Alzheimer's disease and mild cognitive impairment.

Brendan J Kelley1, Ronald C Petersen.   

Abstract

As our society ages, age-related diseases assume increasing prominence as both personal and public health concerns. Disorders of cognition are particularly important in both regards, and Alzheimer's disease is by far the most common cause of dementia of aging. In 2000, the prevalence of Alzheimer's disease in the United States was estimated to be 4.5 million individuals, and this number has been projected to increase to 14 million by 2050. Although not an inevitable consequence of aging, these numbers speak to the dramatic scope of its impact. This article focuses on Alzheimer's disease and the milder degrees of cognitive impairment that may precede the clinical diagnosis of probable Alzheimer's disease, such as mild cognitive impairment.

Entities:  

Mesh:

Year:  2007        PMID: 17659182      PMCID: PMC2682228          DOI: 10.1016/j.ncl.2007.03.008

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  185 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

Review 3.  Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease.

Authors:  S Borson; M A Raskind
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

4.  Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid.

Authors:  S M Monte; K Ghanbari; W H Frey; I Beheshti; P Averback; S L Hauser; H A Ghanbari; J R Wands
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 5.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

6.  Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance.

Authors:  R J Ivnik; G E Smith; J A Lucas; R C Petersen; B F Boeve; E Kokmen; E G Tangalos
Journal:  Neuropsychology       Date:  1999-01       Impact factor: 3.295

7.  Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975.

Authors:  E Kokmen; C M Beard; K P Offord; L T Kurland
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

8.  A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment.

Authors:  M C Tierney; J P Szalai; W G Snow; R H Fisher; T Tsuda; H Chi; D R McLachlan; P H St George-Hyslop
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

9.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  84 in total

1.  Modeling and Estimating Recall Processing Capacity: Sensitivity and Diagnostic Utility in Application to Mild Cognitive Impairment.

Authors:  Michael K Wenger; Selamawit Negash; Ronald C Petersen; Lyndsay Petersen
Journal:  J Math Psychol       Date:  2010-02-01       Impact factor: 2.223

Review 2.  The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Exp Neurol       Date:  2008-01-26       Impact factor: 5.330

Review 3.  Hypertension and cerebrovascular dysfunction.

Authors:  Costantino Iadecola; Robin L Davisson
Journal:  Cell Metab       Date:  2008-06       Impact factor: 27.287

Review 4.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

5.  Comorbid Alzheimer's disease and OSAS: does CPAP slow cognitive decline?

Authors:  Kathy C Richards
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

Review 6.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

7.  Binary Classification of Alzheimer's Disease Using sMRI Imaging Modality and Deep Learning.

Authors:  Ahsan Bin Tufail; Yong-Kui Ma; Qiu-Na Zhang
Journal:  J Digit Imaging       Date:  2020-10       Impact factor: 4.056

Review 8.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

Review 9.  Omega-3 fatty acids and cognitive function in women.

Authors:  Jennifer G Robinson; Nkechinyere Ijioma; William Harris
Journal:  Womens Health (Lond)       Date:  2010-01

10.  Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein.

Authors:  Laibaik Park; Ping Zhou; Rose Pitstick; Carmen Capone; Josef Anrather; Erin H Norris; Linda Younkin; Steven Younkin; George Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.